Research programme: anti-apoptotic agents - MuriGen Therapeutics
Latest Information Update: 06 Jul 2016
At a glance
- Originator MuriGen Therapeutics
- Mechanism of Action Proto-oncogene protein c-bcl-2 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Inflammation; Thalassaemia; Thrombocytopenia
Most Recent Events
- 06 Jul 2016 Preclinical trials in Thrombocytopenia in Australia (unspecified route)
- 06 Jul 2016 Preclinical trials in Thalassaemia in Australia (unspecified route)
- 06 Jul 2016 Preclinical trials in Inflammation in Australia (unspecified route)